Will the Hikma Pharmaceuticals share price run continue?
In this article we will quickly re-cap the broker forecasts for Hikma Pharmaceuticals (LON:HIK).
The Hikma Pharmaceuticals share price has risen by 1.49% over the past month and it’s currently trading at 2572. For investors considering whether to buy, hold or sell the stock, the question now is whether this price run will continue.
According to the company’s analysts, there are certainly reasons to think it will continue to perform well in the year ahead. In terms of trading recommendations, Hikma Pharmaceuticals currently has:
- 4 Buy recommendations
- 2 Hold recommendations
- 0 Sell recommendations
This suggests that analysts are generally positive about the outlook.
Questioning broker positivity
At its current price of 2572, shares in Hikma Pharmaceuticals are trading at a discount of -9.03% to its 52 week high price. The 1-year performance of the shares has been 26.5%.
While analyst forecasts can be a useful guide to what City 'experts' think about a stock's near term future, they can be unreliable. To get a better idea about the strengths and weaknesses of Hikma Pharmaceuticals it's worth doing some investigation yourself. Indeed, we've identified some areas of concern with Hikma Pharmaceuticals that you can find out about here.
About us
Stockopedia helps individual investors make confident, profitable choices in the stock market. Our StockRank and factor investing toolbox unlocks institutional-quality insights into thousands of global stocks. Voted “Best Investment Research Tools” and “Best Research Service” at the 2021 UK Investor Magazine awards.